317 related articles for article (PubMed ID: 19672905)
1. Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo.
Redmond WL; Gough MJ; Weinberg AD
Eur J Immunol; 2009 Aug; 39(8):2184-94. PubMed ID: 19672905
[TBL] [Abstract][Full Text] [Related]
2. Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist.
Redmond WL; Gough MJ; Charbonneau B; Ratliff TL; Weinberg AD
J Immunol; 2007 Dec; 179(11):7244-53. PubMed ID: 18025166
[TBL] [Abstract][Full Text] [Related]
3. Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression.
Redmond WL; Triplett T; Floyd K; Weinberg AD
PLoS One; 2012; 7(4):e34467. PubMed ID: 22496812
[TBL] [Abstract][Full Text] [Related]
4. Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.
Linch SN; Kasiewicz MJ; McNamara MJ; Hilgart-Martiszus IF; Farhad M; Redmond WL
Proc Natl Acad Sci U S A; 2016 Jan; 113(3):E319-27. PubMed ID: 26729864
[TBL] [Abstract][Full Text] [Related]
5. In vivo antitumor function of tumor antigen-specific CTLs generated in the presence of OX40 co-stimulation in vitro.
Pham Minh N; Murata S; Kitamura N; Ueki T; Kojima M; Miyake T; Takebayashi K; Kodama H; Mekata E; Tani M
Int J Cancer; 2018 Jun; 142(11):2335-2343. PubMed ID: 29313971
[TBL] [Abstract][Full Text] [Related]
6. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.
Redmond WL; Linch SN; Kasiewicz MJ
Cancer Immunol Res; 2014 Feb; 2(2):142-53. PubMed ID: 24778278
[TBL] [Abstract][Full Text] [Related]
7. OX40 and Bcl-xL promote the persistence of CD8 T cells to recall tumor-associated antigen.
Song A; Tang X; Harms KM; Croft M
J Immunol; 2005 Sep; 175(6):3534-41. PubMed ID: 16148096
[TBL] [Abstract][Full Text] [Related]
8. Anti-OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses.
Ruby CE; Redmond WL; Haley D; Weinberg AD
Eur J Immunol; 2007 Jan; 37(1):157-66. PubMed ID: 17183611
[TBL] [Abstract][Full Text] [Related]
9. Intracellular Galectin-3 Is Essential for OX40-Mediated Memory CD8
Amani MF; Rolig AS; Redmond WL
J Immunol; 2020 Oct; 205(7):1857-1866. PubMed ID: 32848035
[TBL] [Abstract][Full Text] [Related]
10. OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen.
Murata S; Ladle BH; Kim PS; Lutz ER; Wolpoe ME; Ivie SE; Smith HM; Armstrong TD; Emens LA; Jaffee EM; Reilly RT
J Immunol; 2006 Jan; 176(2):974-83. PubMed ID: 16393983
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ.
Moran AE; Polesso F; Weinberg AD
J Immunol; 2016 Sep; 197(6):2509-21. PubMed ID: 27503208
[TBL] [Abstract][Full Text] [Related]
12. Enhancing the Generation of Eomes
Emerson DA; Rolig AS; Redmond WL
Cancer Immunol Res; 2021 Apr; 9(4):430-440. PubMed ID: 33593794
[TBL] [Abstract][Full Text] [Related]
13. IL-12 is required for anti-OX40-mediated CD4 T cell survival.
Ruby CE; Montler R; Zheng R; Shu S; Weinberg AD
J Immunol; 2008 Feb; 180(4):2140-8. PubMed ID: 18250420
[TBL] [Abstract][Full Text] [Related]
14. Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells.
Takeda I; Ine S; Killeen N; Ndhlovu LC; Murata K; Satomi S; Sugamura K; Ishii N
J Immunol; 2004 Mar; 172(6):3580-9. PubMed ID: 15004159
[TBL] [Abstract][Full Text] [Related]
15. Regulation of A1 by OX40 contributes to CD8(+) T cell survival and anti-tumor activity.
Lei F; Song J; Haque R; Haque M; Xiong X; Fang D; Croft M; Song J
PLoS One; 2013; 8(8):e70635. PubMed ID: 23936461
[TBL] [Abstract][Full Text] [Related]
16. CD134 Costimulation Couples the CD137 Pathway to Induce Production of Supereffector CD8 T Cells That Become IL-7 Dependent.
Lee SJ; Rossi RJ; Lee SK; Croft M; Kwon BS; Mittler RS; Vella AT
J Immunol; 2007 Aug; 179(4):2203-14. PubMed ID: 17675480
[TBL] [Abstract][Full Text] [Related]
17. Functional similarity and differences between selection-independent CD4-CD8- alphabeta T cells and positively selected CD8 T cells expressing the same TCR and the induction of anergy in CD4-CD8- alphabeta T cells in antigen-expressing mice.
Caveno J; Zhang Y; Motyka B; Teh SJ; Teh HS
J Immunol; 1999 Aug; 163(3):1222-9. PubMed ID: 10415017
[TBL] [Abstract][Full Text] [Related]
18. Costimulation of CD8 T cell responses by OX40.
Bansal-Pakala P; Halteman BS; Cheng MH; Croft M
J Immunol; 2004 Apr; 172(8):4821-5. PubMed ID: 15067059
[TBL] [Abstract][Full Text] [Related]
19. The role of OX40-mediated co-stimulation in T-cell activation and survival.
Redmond WL; Ruby CE; Weinberg AD
Crit Rev Immunol; 2009; 29(3):187-201. PubMed ID: 19538134
[TBL] [Abstract][Full Text] [Related]
20. Ox40 costimulation enhances the development of T cell responses induced by dendritic cells in vivo.
De Smedt T; Smith J; Baum P; Fanslow W; Butz E; Maliszewski C
J Immunol; 2002 Jan; 168(2):661-70. PubMed ID: 11777959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
